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Summary The acetylator phenotype was determined in 100 patients with breast cancer and 100 control
female subjects using isoniazid. The proportion of fast acetylators in the breast cancer patients (43%) was not
significantly different from the control group (43%). We conclude that acetylator phenotype is unlikely to be
an important determinant of the risk of developing breast cancer.
Drug acetylation is a conjugation mechanism whereby com-
pounds are linked with acetyl coA to form generally (but not
always) inert, acetylated metabolites. The rate of acetylation
is inherited as an autosomal recessive gene and in the normal
Caucasian population approximately 53-62% of subjects are
slow acetylators (McQueen, 1980). It has been suggested that
the prevalence of fast acetylator phenotype is much higher in
patients with breast cancer (Bulovskaya et al., 1978). It has
also been shown that certain strains of mice with the
capability to acetylate drugs rapidly also have a higher risk
of spontaneously occurring breast tumours (Bulovskaya,
1976). A postulated mechanism for this relationship was that
dietary amines may acetylate to carcinogenic metabolites
which may increase the risk of breast cancer in fast acetyl-
ators. However, the only human study was small, involved
patients with advanced breast carcinoma and was performed
using older substrates for acetylation which have now been
superseded by more satisfactory methods (Bulovskaya et al.,
1978). We therefore decided to investigation the acetylator
status of patients with less advanced breast cancer, using a
simple, recently developed method to measure acetylator
status (Hutchings & Routledge, 1986).
Subjects and methods
Women undergoing investigation of breast masses were
approached to take part in the study, which had received
ethical approval from the local Ethics Committee. After fully
informed written consent had been obtained, a single tablet
of isoniazid 200mg was given after an overnight fast and
blood sampled at 3 h for measurement of the ratio of
acetylisoniazid to isoniazid by high performance liquid
chromatography (Hutchings et al., 1983a). Samples were
stored at -70°C before assay in order to avoid breakdown
of isoniazid (Hutchings et al., 1983b). Subjects with histo-
logically proven carcinoma of the breast were included in the
breast cancer group. In addition, 48 subjects whose breast
carcinoma had been previously diagnosed and who had
previously undergone mastectomy were also studied. Some
of these patients were receiving adjuvant tamoxifen. None
were receiving cytotoxic agents. All breast cancer patients
were Caucasian.
The control group consisted of 32 Caucasian patients with
breast lumps in whom abnormalities of normal development
or involution (ANDI) were subsequently diagnosed histo-
logically (Hughes et al., 1987), or healthy Caucasian drug-
free volunteers recruited at a local factory.
Results
One hundred patients with breast carcinoma and 100 female
controls were studied. The proportions of slow and fast
acetylators in each group are shown in Table I and a
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histogram of the ratios of acetylisoniazid to isoniazid
(ACINH/INH ratio) for the two groups is shown in Figure
1. The proportion of fast acetylators (13/32) and slow
acetylators (19/32) was identical in benign breast disease to
the proportions in the healthy control females (26/68 and
40/68, respectively) so the two groups were combined as the
control group. There was no significant difference between
the proportion of slow and fast acetylators in the control
group and the patients with breast cancer (P>0.05). The
relative risk of breast cancer in the fast acetylator phenotype
was 1.05 (95% confidence interval 0.76-1.45).
Table I Proportions of fast and slow acetylators in
each group
Acetylator
phenotype
Group No. of cases Fast Slow
Breast cancer 100 43 57
Control 100 41 59
X2=0.082; P>0.05.
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Figure 1 Proportion of slow (plasma ACINH/INH ratio <1.5)
and fast acetylators in 100 breast cancer (a) and 100 control (b)
groups. The dotted line indicates the separation between the slow
(left hand side) and fast (right hand side) acetylators.
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Discussion
The results of this study contrast with those previously
reported in breast carcinoma in which 68% of breast cancer
patients but only 37% of controls were of the fast acelylator
phenotype (Bulovskaya et al., 1978). However, the propor-
tion of fast acetylators in both the breast cancer and control
groups in our study is very similar to that reported by
several authors for normal Caucasion populations (38-47%)
(McQueen, 1980). There are several possible reasons for the
discrepancy between this and the previous study. The first
report included only 79 subjects whereas this study involves
over twice as many subjects (200). Secondly Bulovskaya et
al.'s study involved a more heterogeneous population of
patients with a higher proportion of subjects suffering from
advanced breast carcinoma and receiving many drugs. This
report includes patients with recently diagnosed breast carci-
noma who are therefore drug-free and otherwise well.
Finally the previous study used a single plasma sample after
administration of sulphadimidine, this drug is highly bound
to plasma albumin (>90%). In patients with advanced breast
disease it is possible that hypoalbuminaemia may have been
present. If so total sulphadimidine clearance and therefore
plasma concentrations of sulphadimidine and acetylsulpha-
dimidine may have been altered as a result. It is also known
that single sample tests based on sulphadimidine are unreli-
able in patients with renal dysfunction (Fine & Sumner,
1975) and this may have been present also in some patients
with advanced disease in Bulovskaya's study, although it is
not possible from the details given in the paper to ascertain
this. Neither isoniazid nor acetylisoniazid are appreciably
bound to plasma proteins (Hutchings et al., 1988) and have
a smaller degree of renal clearance and the isoniazid test is
therefore less likely to be affected by renal disease or
hypoalbuminaemia.
In conclusion, we believe that it is unlikely that a fast
acetylator phenotype'redisposes to breast carcinoma or that
breast carcinoma is associated with changes in the rate of
drug acetylation. This does not rule out possible associations
with other genetic polymorphisms of drug metabolism (e.g.
debrisoquine and mephenytoin phenotypes). Factors other
than acetylator status must, however, account for the
increased risk of breast cancer seen in certain families for
example.
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